The protective effect of the RAS inhibitor on diabetic patients with nephropathy in the context of VEGF suppression

Acta Pharmacologica Sinica

Volumn 30, Issue 2, 2009, Pages 242-250

  Chen, Hai Bing ^a   Lu, Jun Xi ^a   Li, Qing ^a   Bao, Yu Qian ^a   Tang, Jun Ling ^a   Lu, Hui Juan ^a   Xiang, Kun San ^a   Jia, Wei Ping ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Albumin excretion rate; Diabetes; Irbesartan; Renin angiotensin system; Vascular endothelium growth factor

Indexed keywords

ALBUMIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; IRBESARTAN; VASCULOTROPIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BIPHENYL DERIVATIVE; TETRAZOLE DERIVATIVE; VASCULOTROPIN A;

ADULT; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DISEASE DURATION; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; KIDNEY FUNCTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; REMISSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT OUTCOME; URINE LEVEL; AGED; CROSS-SECTIONAL STUDY; DISEASE COURSE; DRUG EFFECT; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; URINE;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BIPHENYL COMPOUNDS; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 65349124683     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2008.28     Document Type: Article

References (18)

1. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999; 341: 1127-33.
2. Ziyadeh FN. The extracellular matrix in diabetic nephropathy. Am J Kidney Dis 1993; 22: 736-44.
3. Kim NH, Kim KB, Kim DL, Kim SG, Choi KM, Baik SH, et al. Plasma and urinary vascular endothelial growth factor and diabetic nephropathy in type 2 diabetes mellitus. Diabet Med 2004; 21: 545-51.
4. Lenz T, Haak T, Malek J, Grone HJ, Geiger H, Gossmann J. Vascular endothelial growth factor in diabetic nephropathy. Kidney Blood Press Res 2003; 26: 338-43.
5. Kanesaki Y, Suzuki D, Uehara G, Toyoda M, Katoh T, Sakai H, et al. Vascular endothelial growth factor gene expression is correlated with glomerular neovascularization in human diabetic nephropathy. Am J Kidney Dis 2005; 45: 288-94.
6. Vieitez P, Gomez O, Uceda ER, Vera ME, Molina-Holgado E. Systemic and local effects of angiotensin II blockade in experimental diabetic nephropathy. J Renin Angiotensin Aldosterone Syst 2008; 9: 96-102.
7. Kakizawa H, Itoh Y, Imamura S, Matsumoto T, Ishiwata Y, Ono Y, et al. Possible role of VEGF in the progression of kidney disease in streptozotocin (STZ)-induced diabetic rats: effects of an ACE inhibitor and an angiotensin II receptor antagonist. Horm Metab Res 2004; 36: 458-64.
8. Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS, Schrijvers BF, Tilton RG, Rasch R. Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 2002; 51: 3090-4.
9. Kelly DJ, Buck D, Cox A, Zhang Y, Gilbert RE. Effects on protein kinase C-beta inhibition on glomerular vascular endothelial growth factor expression and endothelial cells in advanced experimental diabetic nephropathy. Am J Physiol Renal Physiol 2007; 293: F565-74.
10. Lee EY, Shim MS, Kim MJ, Hong SY, Shin YG, Chung CH. Angiotensin II receptor blocker attenuates overexpression of vascular endothelial growth factor in diabetic podocytes. Exp Mol Med 2004; 36: 65-70.
11. Kim NH, Oh JH, Seo JA, Lee KW, Kim SG, Choi KM, et al. Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy. Kidney Int 2005; 67: 167-77.
12. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-70.
13. Mogensen CE, Chachati A, Christensen CK, Close CF, Deckert T, Hommel E, et al. Microalbuminuria: an early marker of renal involvement in diabetes. Uremia Invest 1985; 9: 85-95.
14. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS. Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003; 348: 2285-93.
15. Sanchez-Lopez E, Lopez AF, Esteban V, Yague S, Egido J, Ruiz-Ortega M, et al. Angiotensin II regulates vascular endothelial growth factor via hypoxia-inducible factor-1alpha induction and redox mechanisms in the kidney. Antioxid Redox Signal 2005; 7: 1275-84.
16. Liu E, Morimoto M, Kitajima S, Koike T, Yu Y, Shiiki H, et al. Increased expression of vascular endothelial growth factor in kidney leads to progressive impairment of glomerular functions. J Am Soc Nephrol 2007; 18: 2094-104.
17. Chen S, Kasama Y, Lee JS, Jim B, Marin M, Ziyadeh FN. Podocytederived vascular endothelial growth factor mediates the stimulation of alpha3(IV) collagen production by transforming growth factorbeta1 in mouse podocytes. Diabetes 2004; 53: 2939-49.
18. Sano H, Hosokawa K, Kidoya H, Takakura N. Negative regulation of VEGF-induced vascular leakage by blockade of angiotensin II type 1 receptor. Arterioscler Thromb Vasc Biol 2006; 26: 2673-80.